Eikon Therapeutics, Inc. (EIKN) Stock Forecast Oct. 15, 2026
Analysis updated on Oct. 15, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Eikon Therapeutics, Inc. (EIKN) stock forecast summary
Our AI ranks Eikon Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Eikon Therapeutics, Inc. is a small-cap company with a market capitalization of $380M. It ranks number 60 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast. Its P/B Ratio of 0.81x is the lowest of the 50 peers that report one.
For EIKN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 32.0%, measured on 50 forecast dates between 2026-05-11 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -10.0%, measured on 92 forecast dates between 2026-05-11 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.5% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-15 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, EIKN included.
Follow EIKN freeEIKN price chart and AI forecast
How EIKN ranks among 5111 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Eikon Therapeutics, Inc. (EIKN) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | EIKN | Rank |
|---|---|---|
| Market Cap | $380M | 60/60 |
| P/B Ratio | 0.81x | 50/50 |
| Book Value/Share | $8.61 | – |
Financial Health
| Metric | EIKN | Rank |
|---|---|---|
| Current Ratio | 9.89x | 18/59 |
| D/E Ratio | 0.67x | 15/53 |
| Financial Leverage | 1.67x | 15/53 |
| Interest Coverage | -18.5x | 21/39 |
| Working Capital | $492M | 26/59 |
Dividend & Shareholder Information
| Metric | EIKN | Rank |
|---|---|---|
| Shares Outstanding | 54M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $547M | 70.0% of assets |
| Cash & Short-term Investments | $143M | 18.2% of assets |
| Total Liabilities | $313M | 40.0% of assets |
| Short-term Debt | $49M | 6.2% of assets |
EIKN quarterly financials and insider trading
Eikon Therapeutics, Inc. (EIKN) industry peers
Companies classified under the same SEC industry code as Eikon Therapeutics, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| EIKN Eikon Therapeutics, Inc. | ▲ | $380M |
| AMGN Amgen Inc | ▼ | $234.65B |
| GILD Gilead Sciences, Inc. | ▲ | $190.38B |
| MRNA Moderna, Inc. | ▲ | $90.35B |
| ARGX Argenx Se | ▼ | $52.37B |
| RVMD Revolution Medicines, Inc. | ▲ | $41.48B |
| BIIB Biogen Inc. | ▼ | $34.16B |
| BNTX Biontech Se | ▲ | $22.42B |
| EXEL Exelixis, Inc. | ▶ | $15.11B |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.82B |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.26B |
| TECH Bio-Techne Corp | ▼ | $11.37B |
| IBRX Immunitybio, Inc. | ▲ | $10.50B |
| RGEN Repligen Corp | ▶ | $10.06B |
| PCVX Vaxcyte, Inc. | ▲ | $10.05B |
| QGEN Qiagen N.V. | ▶ | $9.88B |
| KRYS Krystal Biotech, Inc. | ▶ | $9.79B |
| TWST Twist Bioscience Corp | ▲ | $9.29B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.88B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.44B |
| IMVT Immunovant, Inc. | ▲ | $5.76B |
| CGON Cg Oncology, Inc. | ▲ | $5.48B |
| KOD Kodiak Sciences Inc. | ▲ | $5.10B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.86B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.82B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $4.08B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.74B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.17B |
| DNLI Denali Therapeutics Inc. | ▼ | $2.86B |
| LIFE Atyr Pharma Inc | ▲ | $2.46B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.44B |
| ADMA Adma Biologics, Inc. | ▼ | $2.40B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.25B |
| NVAX Novavax Inc | ▲ | $2.08B |
| VCEL Vericel Corp | ▲ | $2.06B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.06B |
| ALVO Alvotech | ▲ | $1.90B |
| MESO Mesoblast Ltd | ▶ | $1.77B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.76B |
| IMCR Immunocore Holdings Plc | ▶ | $1.46B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.46B |
| COAG Hemab Therapeutics Holdings, Inc. | ▼ | $1.40B |
| SCNI Scinai Immunotherapeutics Ltd. | ▶ | $1.22B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.14B |
| VOR Vor Biopharma Inc. | ▶ | $1.11B |
| REPL Replimune Group, Inc. | ▲ | $1.07B |
| JATT Zura Bio Ltd | ▶ | $994M |
| VALN Valneva Se | ▼ | $965M |
| IMTX Immatics N.V. | ▲ | $938M |
| MGTX Meiragtx Holdings Plc | ▶ | $904M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $878M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $839M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $798M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $776M |
| SANA Sana Biotechnology, Inc. | ▲ | $698M |
| CADL Candel Therapeutics, Inc. | ▲ | $694M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $674M |
| AURA Aura Biosciences, Inc. | ▲ | $657M |
| SLDB Solid Biosciences Inc. | ▲ | $586M |
| PRME Prime Medicine, Inc. | ▲ | $568M |
Where EIKN sits on the market map
Eikon Therapeutics, Inc. (EIKN) stock news
Loading...
Eikon Therapeutics, Inc. (EIKN) stock forecast FAQ
What is the Eikon Therapeutics, Inc. (EIKN) stock forecast?
Our AI ranks Eikon Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Eikon Therapeutics, Inc. stock predictions?
For EIKN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 32.0%, measured on 50 forecast dates between 2026-05-11 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -10.0%, measured on 92 forecast dates between 2026-05-11 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Eikon Therapeutics, Inc. forecasts updated?
Eikon Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 15, 2026.
Which companies are Eikon Therapeutics, Inc.'s industry peers?
60 issuers in our coverage, EIKN included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.